» Articles » PMID: 19251657

Pulmonary Autoimmunity As a Feature of Autoimmune Polyendocrine Syndrome Type 1 and Identification of KCNRG As a Bronchial Autoantigen

Abstract

Patients with autoimmune polyendocrine syndrome type 1 (APS-1) suffer from multiple organ-specific autoimmunity with autoantibodies against target tissue-specific autoantigens. Endocrine and nonendocrine organs such as skin, hair follicles, and liver are targeted by the immune system. Despite sporadic observations of pulmonary symptoms among APS-1 patients, an autoimmune mechanism for pulmonary involvement has not been elucidated. We report here on a subset of APS-1 patients with respiratory symptoms. Eight patients with pulmonary involvement were identified. Severe airway obstruction was found in 4 patients, leading to death in 2. Immunoscreening of a cDNA library using serum samples from a patient with APS-1 and obstructive respiratory symptoms identified a putative potassium channel regulator (KCNRG) as a pulmonary autoantigen. Reactivity to recombinant KCNRG was assessed in 110 APS-1 patients by using immunoprecipitation. Autoantibodies to KCNRG were present in 7 of the 8 patients with respiratory symptoms, but in only 1 of 102 APS-1 patients without respiratory symptoms. Expression of KCNRG messenger RNA and protein was found to be predominantly restricted to the epithelial cells of terminal bronchioles. Autoantibodies to KCNRG, a protein mainly expressed in bronchial epithelium, are strongly associated with pulmonary involvement in APS-1. These findings may facilitate the recognition, diagnosis, characterization, and understanding of the pulmonary manifestations of APS-1.

Citing Articles

Aire Mutations and Autoimmune Diseases.

Wolff A, Oftedal B Adv Exp Med Biol. 2025; 1471:223-246.

PMID: 40067589 DOI: 10.1007/978-3-031-77921-3_8.


Bronchiectasis in a patient with Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy: a case report.

Silani M, Simonetta E, Gramegna A, De Angelis A, Blasi F, Aliberti S BMC Pulm Med. 2024; 24(1):543.

PMID: 39478519 PMC: 11526547. DOI: 10.1186/s12890-024-03149-9.


Divergent autoantibody and cytokine levels in COVID-19 sepsis patients influence survival.

Kuhn D, Heinen N, Sutter K, Herrmann S, Nocke M, Todt D J Med Virol. 2024; 96(10):e29935.

PMID: 39323094 PMC: 11535095. DOI: 10.1002/jmv.29935.


Retinopathy as an initial sign of hereditary immunological diseases: report of six families and challenges in eye clinic.

Wang Y, Jiang Y, Wang J, Li S, Jia X, Xiao X Front Immunol. 2023; 14:1239886.

PMID: 37711606 PMC: 10498122. DOI: 10.3389/fimmu.2023.1239886.


Dominant-negative heterozygous mutations in AIRE confer diverse autoimmune phenotypes.

Oftedal B, Assing K, Baris S, Safgren S, Johansen I, Jakobsen M iScience. 2023; 26(6):106818.

PMID: 37235056 PMC: 10206195. DOI: 10.1016/j.isci.2023.106818.


References
1.
Betterle C, Greggio N, Volpato M . Clinical review 93: Autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab. 1998; 83(4):1049-55. DOI: 10.1210/jcem.83.4.4682. View

2.
Betterle C, Dal Pra C, Mantero F, Zanchetta R . Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002; 23(3):327-64. DOI: 10.1210/edrv.23.3.0466. View

3.
Kidney J, Lotvall J, Lei Y, Chung K, Barnes P . The effect of inhaled K+ channel openers on bronchoconstriction and airway microvascular leakage in anaesthetised guinea pigs. Eur J Pharmacol. 1996; 296(1):81-7. DOI: 10.1016/0014-2999(95)00670-2. View

4.
Falorni A, Ortqvist E, Persson B, Lernmark A . Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Methods. 1995; 186(1):89-99. DOI: 10.1016/0022-1759(95)00139-2. View

5.
Small R, Berry J, Foster R . Potassium channel opening drugs and the airways. Braz J Med Biol Res. 1992; 25(10):983-98. View